#fbio

[philoursmars]

Je reviens à mon projet de présenter la plupart de mes 55000 photos (nouveau compte approximatif. On se rapproche du présent !).

2015. A Lille, sur la rue Faiderbe, les “Ramblas Brésiliennes” de Fabio Ricardo.

[arunarura]

Cooking Flexibility at Its Finest with FABER’s FBIO 80L 6F Microwave!

The FABER 80 L Convection Microwave Oven, model FBIO 80L 6F in Silver, is an impressive and versatile addition to any kitchen. With an extensive 80-liter capacity, this oven is designed to accommodate large meals, making it a suitable choice for larger families or anyone who loves cooking and entertaining. Here’s a detailed look at its features and benefits:

Key Features

1. Large Capacity

The 80-liter capacity is a standout feature of this microwave oven. It is one of the largest convection microwave ovens on the market, allowing users to prepare large meals in one go. Whether you need to bake a big batch of cookies, roast a whole chicken, or reheat multiple dishes, this microwave oven can accommodate large cookware, making it perfect for family gatherings and events.

2. 6-in-1 Multi-Functionality

This model combines the functions of a microwave, convection oven, and grill, offering six different cooking modes. The versatility allows users to bake, grill, roast, and cook a variety of dishes. The convection function ensures even heat distribution, making it suitable for baking and roasting, while the grill option allows for delicious, evenly cooked meats and vegetables.

3. User-Friendly Digital Controls

The FABER FBIO 80L 6F is equipped with a digital control panel that offers easy navigation and functionality. With clearly labeled buttons, users can choose the desired cooking mode, adjust the time and temperature, and select preset cooking programs. The digital display enhances accuracy, ensuring precise control over the cooking process for consistent results.

4. Stainless Steel Interior

Featuring a stainless steel interior, this oven is designed for durability and efficient cooking. Stainless steel not only improves heat retention and distribution but also simplifies cleaning, as it’s resistant to food stains and odors. The smooth surface prevents food from sticking, which reduces the need for heavy scrubbing and helps maintain a hygienic cooking environment.

5. Advanced Safety Features

Safety is a key consideration in this model, as it includes a range of safety features such as a child lock, overheating protection, and an automatic shut-off function. The child lock prevents accidental use by young children, while the overheating protection ensures safe operation by preventing the appliance from exceeding safe temperatures. These features make it a family-friendly option.

6. Sleek, Modern Design

With its silver finish and minimalist design, the FABER FBIO 80L 6F microwave oven adds a touch of sophistication to any kitchen. Despite its large capacity, the oven maintains a sleek appearance and can fit well in most kitchen setups, whether placed on a countertop or integrated into cabinetry.

Benefits of Using the FABER 80 L Convection Microwave Oven

Time and Energy Efficiency

The convection and grill functions enable quicker, more energy-efficient cooking than standard microwave-only models. Convection technology speeds up cooking by distributing heat evenly, making this oven a time-saver for busy families.

Flexible Cooking Options

With six cooking modes, this appliance offers flexibility, catering to different cooking styles and cuisines. Whether you're defrosting ingredients, baking a dessert, or grilling a main course, it has options to suit various needs.

Healthier Cooking Alternatives

The oven provides healthier cooking options through its grill and convection features. Grilling and roasting can reduce the need for excess oil, and convection cooking preserves nutrients, allowing for more nutritious meals.

Ideal for Batch Cooking

The large capacity makes it easy to cook multiple dishes simultaneously, making it ideal for batch cooking. This is particularly beneficial for families or anyone looking to prep meals in advance.

Conclusion

The FABER 80 L Convection Microwave Oven FBIO 80L 6F (Silver) is an exceptional choice for anyone looking for a powerful, versatile, and stylish appliance. Its extensive capacity and six-in-one functionality make it ideal for larger households and those who frequently entertain guests. The stainless steel interior, advanced safety features, and user-friendly controls add further convenience, while the sleek design ensures it fits well in a modern kitchen.

This microwave oven is a great investment for those who need both capacity and versatility. While it requires more space and may consume slightly more power than smaller ovens, its functionality and efficiency make it well worth the investment for anyone who loves to cook and experiment in the kitchen.

Buy the Latest FABER 80 L Convection Microwave Oven, FBIO 80L 6F Silver Online @ Best Prices in Poorvika!

Click here: https://www.poorvika.com/faber-80-l-convection-microwave-oven-fbio-80l-6f-silver/p

[7ooo-ru]

Естественные шевелюры

Это не сгенерировано AI, это совершенно реальные работы бразильского художника Фабио Гомеша Триндаде (Fbio Gomes Trindade) - он использует реальные деревья в качестве "волос" для своих портретов. Вот его Инстаграм.

А вот он сам рядом со св��ей работой.

Подробнее https://7ooo.ru/group/2024/04/29/007-estestvennye-shevelyury-grss-303327703.html

[nuovaalta2]

$FBIO #

The text does not mention when the financial results release will be for Fortress Biotech, Inc. It only mentions that Lindsay A. Rosenwald, M.D. will participate in a fireside chat at the 36th Annual ROTH Conference on March 18, 2024. https://csimarket.com/stocks/at_glance.php?code=FBIO&utm_source=dlvr.it&utm_medium=tumblr

[hopetribune]

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

http://dlvr.it/T2LCy8

[columbianewsupdates]

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

http://dlvr.it/T2LCRF

[conversationpoint]

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

http://dlvr.it/T2L8pH

[desmoinesnewsdesk]

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

http://dlvr.it/T2L7Kj

[fmarkets]

Breakthrough Financial Success: Fortress Biotech Inc Soars with Revenue Surge and Improved EPS https://csimarket.com/stocks/news.php?code=FBIO&date=2023-11-17154446&utm_source=dlvr.it&utm_medium=tumblr

[cavenewstimes]

Fortress Biotech (FBIO) Price Target Increased by 6.11% to 7.79

The typical 1 year rate target for Fortress Biotech (NASDAQ: FBIO) has actually been modified to 7.79/ share. This is a boost of 6.11% from the previous price quote of 7.34 outdated August 31, 2023. The cost target is approximately numerous targets supplied by experts. The …Read More

[illustir]

I'm not sure what lesson to take from the Frankenstein end state of the Facebook iOS app. Is it that mobile does not really scale? Or is it that you shouldn't scale mobile in this way?

[fahrni]

Saturday Morning Coffee

I’ve had a head cold for the past week and my body is finally getting on top of it, finally. As a result I’m tired this morning and my brain is foggy and doesn’t want to do anything. Coffee to the rescue, I hope! ☕️

Hope you enjoy the links.

CNN

More than 23,000 people have been killed and tens of thousands injured after a magnitude 7.8 earthquake struck Turkey and Syria on Monday, officials said.

It’s been a very sad week for the people of Turkey and Syria. So many dead and wounded. I haven’t kept up with it like I normally would for such a tragedy. Why is that?

Thankfully people are still being rescued from the rubble. America needs to send help.

Arstechnica

According to The Register, Google and Mozilla have recently been spotted working on versions of Chromium and Firefox that use their normal Blink and Gecko rendering engines, respectively.

It doesn’t surprise me to hear Google and Mozilla have native browsers built for iOS. Why not, their code is very portable already, it makes sense.

Some competition on the platform would be good for Apple and consumers.

Colm Doyle

It’s hardly insightful to suggest that the last few years have substantially changed the day to day experience of a knowledge worker. Nearly overnight even the most remote skeptical leadership teams were forced to embrace flexible work practices like working from home.

At WillowTree our CEO, Tobias, is a huge proponent of working in the office full time. When COVID hit we were just getting ready to move into our newly renovated building at Woolen Mills, but that didn’t happen and everybody went remote.

Fast forward a year and a half later and WillowTree is making preparations to return to the office on a hybrid schedule. Then COVID spiked again so it was out on hold. Eventually a poll was taken, we do lots of polls at WillowTree, asking if folks preferred in office or work from home. Tobias himself was shocked to learn that over 20% of the company preferred it.

Things changed based on the poll and a team was created to that would allow anyone to work from anywhere. I’m part of that team and I love it. I’m grateful our leadership is open to big change. So far it’s been really amazing.

Facebook Engineering Blog

Facebook for iOS (FBiOS) is the oldest mobile codebase at Meta. Since the app was rewritten in 2012, it has been worked on by thousands of engineers and shipped to billions of users, and it can support hundreds of engineers iterating on it at a time.

If you’re a developer go read this piece. When folks think of mobile software they most likely think of toy sized apps like Stream, not a lot going on. Then you run into a beast of a codebase like Facebook and you realize mobile software is “real” bonafide software with real challenges.

Mike Masnick

In the past few decades, however, rather than building new protocols, the internet has grown up around controlled platforms that are privately owned.

This is a piece from 2019 and it holds up really well. He’s basically discussing what ActivityPub and Mastodon have become. A lot of the challenges around siloed social networks is around “free speech.” I put that in quotes because most folks think free speech is a free for all, anything goes, and you can’t ban me because I said something nasty or threatening to you. Of course a platform could ban you and it has nothing to do with free speech. Companies and individuals don’t have to take the abuse and can choose to ban you if they want. Mastodon has helped this in many ways. I run my own Mastodon server and it’s by invitation only so I know and trust the folks on it to maintain a certain decorum. I know they won’t be nasty or threatening and it’s self policing. We need more small instances with better community management.

Cloudflare

Today we’re introducing Wildebeest, an open-source, easy-to-deploy ActivityPub and Mastodon-compatible server built entirely on top of Cloudflare’s Supercloud.

I read through this post and I think it’s really wonderful to see addition ActivityPub based services come online. It’s an exciting time!

Cordi > About the tech experience on Mastodon. This is the last of three posts I have on Mastodon. I’ve been on the app for more than two months and have been content to ghost Twitter.

A nice series of posts about one persons experience with Mastodon. If you have friends fearful of joining they should go read this and see what someone else has experienced. Sure, it’s not Twitter, it’s even better, and it’s growing day by day.

Jack Dorsey believed Twitter should be open, not a silo. Mastodon and ActivityPub are delivering that vision. A central hub, controlled by a single corporation, is no longer in charge. The people are.

Digits to Dollars

After 30 years of dominance, the industry has come to come view Intel as a giant who has fallen on hard times. We do not think this is the right way to view the company, and it creates mental blind spots which hinder our ability to assess what are the right next steps for the company.

It’s hard to believe Intel is having so much trouble. They coasted for so long on their x86 architecture and still make a ton of money from it but the times they are a changing. Apple creating their own, much better, silicon must scare the pants off of Intel internally. They’re lucky Apple doesn’t care to sell their tech to any computer manufacturer. Imagine a Windows PC running on Apple Silicon. That would be glorious. 😃

Dave Rogers

What is somewhat more puzzling to me is the nature or character of the people who are attracted to this type. The toadies and sycophants, the enablers and lickspittles who compete for proximity to someone in power, someone in control.

I love reading Dave’s stuff. He’s an extremely kind, compassionate, man and a great writer. Unfortunately he lives in Florida and that state is full of looney birds, especially at the government level. Their Governor is is King Looney, a complete nutter, with fantasies of making Florida a totalitarian government run by him. His desire to control everything is exactly the opposite of a free nation and against everything our nation was founded on. He needs to go.

Dave, like many of us, can’t understand why people want this sort of strongman creating horrible policy in charge. Why would you want your rights squashed? You’re American, don’t you believe in freedom for all?

[arunarura]

Bake, Grill, Roast with FABER 80L Build-in Microwave Oven at Poorvika!

The FABER 80 L Built-in Microwave Oven, FBIO 80L 4F BK Black is a premium kitchen appliance designed to bring efficiency, versatility, and style to modern kitchens. Faber is a well-known brand in the home appliance sector, and this built-in microwave oven is a testament to its commitment to quality and innovation. The oven, with its large 80-liter capacity, is ideal for households that require a reliable, multi-functional appliance for various cooking needs.

Design and Build Quality

The FBIO 80L 4F BK Black microwave oven boasts a sleek and contemporary design, making it a perfect fit for modern kitchens. Its black finish provides a sophisticated touch that seamlessly integrates with kitchen décor. Being a built-in model, it saves valuable counter space while giving the kitchen a clutter-free and polished look.

The stainless-steel cavity ensures durability, making the oven resistant to wear and tear from regular usage. The door, fitted with tempered glass, provides both safety and insulation while offering a clear view of the cooking process inside. This combination of durability and aesthetics enhances the overall value of the appliance.

Capacity

One of the standout features of the Faber FBIO 80L 4F BK is its impressive 80-liter capacity, which is larger than standard microwaves. This large space makes it ideal for preparing large meals or multiple dishes simultaneously, catering to big families or social gatherings. Whether you're baking, roasting, grilling, or reheating, the microwave can accommodate substantial quantities, making meal preparation more efficient.

Functionality

The Faber FBIO 80L 4F BK microwave oven is a multifunctional appliance that comes equipped with a variety of cooking modes, including microwave, convection, grill, and combination modes. This allows users to switch between cooking methods based on their requirements, whether it's a simple reheating task or preparing elaborate meals.

The convection mode is especially useful for baking and roasting, ensuring even cooking by circulating hot air throughout the oven. The grill mode gives a crispy, browned finish to dishes, perfect for items like pizza, kebabs, or toast. Additionally, the microwave function allows for rapid heating, defrosting, and cooking, offering a versatile cooking experience for users.

User-friendly Features

This model is equipped with digital touch controls, which provide a user-friendly interface to manage various cooking functions and set precise temperatures and timings. The LED display enhances usability, allowing users to monitor cooking times and modes with ease. The oven also includes preset cooking programs that automate the process for specific dishes, making meal preparation simpler even for novice cooks.

Safety and Energy Efficiency

Faber has prioritized safety in the FBIO 80L 4F BK, offering child lock features to prevent accidents, especially in households with children. Additionally, the oven is designed with energy-efficient technology that ensures optimal energy use, which helps reduce electricity consumption and minimizes environmental impact.

Conclusion

The FABER 80 L Built-in Microwave Oven, FBIO 80L 4F BK Black is a high-performance, versatile appliance that combines a large capacity with multiple cooking functions, making it an excellent choice for families or individuals who enjoy cooking. Its sleek design, user-friendly features, and energy efficiency make it a practical yet stylish addition to any modern kitchen.

Buy the Latest Faber 80l Build-in Microwave Oven Online @ Best Price in Poorvika!

Click here: https://www.poorvika.com/faber-80-l-built-in-microwave-oven-fbio-80l-4f-bk-black/p

[stocklivemarket]

Here's what we can say about RIGL stock. A biotechnology business called Rigel Pharmaceuticals, Inc. finds and creates small molecule medications to treat cancer, uncommon immunological illnesses, and hematologic disorders. The business provides adults with chronic immune neutropenia Tavalisse, an oral splenic inhibitor of tyrosine kinase. Additionally, it produces the drug Fostamatinib, which is currently undergoing phase III clinical trials for the treatment of COVID-19, warm autoimmune hemolytic anemia, and COVID-19 patients who are hospitalized. The company is also working on R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor, which has successfully completed a phase I clinical trial for autoimmune and inflammatory diseases. As well as R289, a verbal interleukin understanding of the mechanism kinase 1/4 inhibitor, which is in phase I randomized study for autoimmune, inflammatory, and hematology-oncology diseases. Who Owns RIGL? Institutional investors own 73.88% of Rigel Pharmaceuticals (NASDAQ: RIGL), while insiders own 15.05% and individual investors own 11.07%. The largest individual shareholder of RIGL stock is Bvf Partners L P, which holds 16.66M shares, or 9.64% of the firm. Shares of Rigel Pharmaceuticals owned by Bvf Partners L P are presently valued at $13.89M. About RIGL It has research and license contracts with AstraZeneca AB for the development and marketing of R256, an inhaled JAK inhibitor, with BerGenBio AS for the development and marketing of AXL inhibitors in oncology, with Daiichi Sankyo for the development of murine double minute 2 inhibition for solid and cytological malignancies, and with Kissei Pharmaceutical Co., Ltd. for the licensing and supply of Fostamatinib. Additionally, the business and Eli Lilly and Company have a license agreement and a strategic partnership to co-develop and market R552 for a variety of indications, including inflammatory and autoimmune illnesses and other non-CNS disease development candidates. South San Francisco, California serves as the corporate headquarters for Rigel Pharmaceuticals, Inc. What Are The Consensus Ratings And Price Objective For Rigel Pharmaceuticals? The consensus recommendation for RIGL stock, based on the present 4 hold ratings and 3 buy ratings for RIGL stock, is Hold according to the ratings that 7 analysts have issued over the past year. With a high price goal of $15.00 and a low cost target of $1.00, Rigel Pharmaceuticals' average 12 month price forecast is $3.96. NASDAQ ticker RIGL stock is used to identify Rigel Pharmaceuticals when trading on the NASDAQ. Stock quotations for Rigel Pharmaceuticals may alternatively be shown as NASDAQ: RIGL. The current share price for Rigel Pharmaceuticals is $0.83 (NASDAQ: RIGL) (as of Dec 2, 2022). (NYSE MKT: RIGL) There are now 172,836,336 shares of Rigel Pharmaceuticals outstanding. The market capitalization of Rigel Pharmaceuticals is $144.15M, with the stock now selling at $0.83 per share. On November 29, 2000, RIGL stock went public at a price of $63.99. Your return over the past 22 years if you had purchased RIGL stock at $63.99 would have been -98.7%, for just an annualized return of -17.9%. Competitors Of RIGL Verastem (VSTM), Spectrum Pharmaceuticals (SPPI), Merrimack Pharmaceuticals (MACK), Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), Infinity Pharmaceuticals (INFI), Clovis Oncology (CLVS), Molecular Templates (MTEM), XOMA (XOMA), and Lexicon Pharmaceuticals are some of Rigel Pharmaceuticals' primary rivals (LXRX). Each of these businesses belongs to the "biotechnology" sector. Analysts favor other medical firms more than Rigel Pharmaceuticals. While the typical consensus recommendation for medical firms is Buy, Rigel Pharmaceuticals' rating is Hold. Verastem And Rigel Pharmaceuticals Verastem is outperformed by Rigel Pharmaceuticals in terms of earnings and revenue. Rigel Pharmaceuticals is currently the more cost-effective of the two stocks as it is selling at a cheaper cost ratio than Verastem.

With a beta of 0.63, Verastem's share price is predicted to be 37% less volatile than that of the S&P 500. When compared to the S&P 500, Rigel Pharmaceuticals does have a beta of 1.25, indicating that its RIGL stock price is 25% more volatile. When compared by MarketBeat users, Verastem received 150 more exceed votes than Rigel Pharmaceuticals. However, just 67.24% of individuals chose to vote for Verastem to outperform, compared to 69.61% who chose Rigel Pharmaceuticals. Institutional investors hold 58.6% of the shares of Verastem. Institutional investors now hold 80.9% of the shares of Rigel Pharmaceuticals. Insiders are the owners of 2.9% of the Verastem stock. Insiders own 6.4% of the shares of Rigel Pharmaceuticals, in contrast. A company's solid organizational ownership is a sign that hedge funds, big money managers, and endowments think it's prepared for long-term success. With a current consensus price objective of $5.00, Verastem might rise by 1,041.03%. With a $3.96 consensus price objective, Rigel Pharmaceuticals may rise by 374.91% from current levels. Analysts clearly perceive Verastem as being more favorable as Rigel Pharmaceuticals, given its higher consensus rating and more potential upside. What Date Will Rigel Pharmaceuticals Report Earnings? However, based on the report dates from the previous year, Rigel Pharmaceuticals estimates that its next earnings day will be on Tuesday, March 7, 2023. Rigel Pharmaceuticals (NASDAQ:RIGL) topped the analysts' consensus expectation of ($0.13) by $0.02 with its ($0.11) earnings per share (EPS) for the prior quarter. The reported yearly revenue for Rigel Pharmaceuticals (NASDAQ:RIGL) is $149.24 million. The reported net income for Rigel Pharmaceuticals (NASDAQ:RIGL) is -$17.91 million. Over the previous four quarters, RIGL's earnings per share were negative $0.48. Most Recent Analyst Recommendations From RIGL On December 2, 2022, Yigal Nochomovitz, a Citigroup bottom 6% analyst, increases RIGL to a solid investment rating. On November 4, 2022, Gary Nachman, a bottom 13% economist with BMO Capital, lowers their price objective for RIGL from $4 to $3 while maintaining a Buy recommendation. On August 18, 2022, Joseph Pantginis, rated bottom 10% analyst with HC Wainwright & Co., keeps RIGL with the a buy rating and increases their price objective from $7.00 to $15.00. On August 17, 2022, Do Kim, a high 33% analysts from Piper Sandler, retains RIGL with a hold recommendation and increases their price objective for the RIGL stock from $1.00 to $2.00. Financial Summary For RIGL Financial due diligence studies that RIGL passed show that it has a 70748000 cash burn. It has at least a year's worth of coverage in the form of cash and short-term investments. On the RIGL cash balance, short-term assets outnumber long-term liabilities. On the RIGL accounting records, short-term assets exceed short-term liabilities. Financial Due Diligence Tests that Fail: In the previous year, RIGL's profit margin decreased from -9.9% to -92.4%. The RIGL ratio of debt to equity is negative at -6.83. The total debt of RIGL is still negative. RIGL has $81.64M in short-term investments and cash. This is insufficient to fund its $70.75M yearly cash burn. Asset To Liability Ratio There are more short-term assets ($110.44M) than short-term liabilities ($47.27M) for RIGL. Long-term liabilities ($88.18M) are less than short-term assets ($110.44M) for RIGL. Since RIGL's debt to shareholder equity ratio (-6.83) is still negative, we do not take into account whether debt has decreased over the last five years. It is more concerning than a high ratio when RIGL's proportion of debt to equity (-6.83) is negative. Cash burn for the upcoming year ($70.75M) exceeds RIGL's cash & short-term investments ($81.64M). The profit margin for RIGL dropped by (-82.5%) in the previous year, going from (-9.9%) to (-92.4%). For at least a year, RIGL's cash & short-term investment ($81.64M) can fund its cash burn ($70.75M).

When factoring in a healthy margin of safety, RIGL ($0.83) is not considerably low (2.67%) in comparison to our estimate of its market valuation price of $0.86 based on the discounted cash flow (DCF) modeling. Scoring For RIGL Value: RIGL has a Value score of 14, which is higher than the industry average for Biotechnology. Right now, only one of RIGL's seven due diligence checks is passing. Finances: RIGL has a Financials score of 11, which is higher than the industry average for the Biotechnology sector. Only one of RIGL's seven due diligence checks is being passed. Forecast: The RIGL forecast score is 0, that is the same as the mean for the biotechnology sector. RIGL is failing 0 of 9 checks for due diligence. Performance: RIGL has a performance score of 43, which is higher than the average for the biotechnology sector. 3 from out 10 due diligence processes are being passed by RIGL. Dividend: Considering Rigel Pharmaceuticals hasn't recently paid dividends, we don't assign a score to this factor. How To Purchase Rigel Pharmaceuticals Stock Here are the six steps once more for purchasing Rigel Pharmaceuticals shares. Find out where to purchase shares in Rigel Pharmaceuticals. Open an account with a brokerage. Add your information after selecting your preferred payment method. Your brokerage account with the money. Analyze the shares of Rigel Pharmaceuticals. Purchase your RIGL product. Select whether you want to acquire RIGL stock at the spot price or at a preset price using a limit order. Get up-to-date information regarding your RIGL stock position. Make a watchlist of important changes regarding your new RIGL stock purchase.   RIGL Stock Forecast 2022 Six Wall Street analysts who follow NASDAQ: RIGL agree that the RIGL stock is a buy. Out of 6 analysts, 0 (%) suggest RIGL as a Sell, 0 (%) recommend RIGL as a Strong Sell, 1 (16.67%) recommends RIGL as a Strong Buy, 2 (33.33%) as a Buy, 3 (50%) as a Hold, and 0 (%) as a Hold Strong Sell. The revenue for Rigel Pharmaceuticals in 2022 is -$82,615,000. The average estimate of RIGL's 2022 profits from 5 Wall Street analysts is -$89,874,895, with the correct figure coming in at -$98,516,712 and the highest estimate coming in at -$81,233,078. RIGL Stock Forecast 2023 With the lowest RIGL earnings projection at -$82,961,441 and the highest RIGL statements forecast at -$36,295,631. 5 Wall Street analysts expect RIGL will earn -$57,035,991 in 2023. RIGL's revenue is expected to be $19,895,363,473 on average by 4 Wall Street analysts in 2023. The lowest RIGL revenue projection is $16,509,326,815, as well as the highest is $25,209,216,624. Analysts predict that RIGL's EPS will just be -$0.33 on average for 2023, with the lowest estimate being -$0.48 and the highest estimate being -$0.21. RIGL Stock Forecast 2024 With the lowest revenue RIGL stock forecast at $18,104,606,196 and the largest income RIGL stock forecast at $31,308,438,085, RIGL is expected to create $23,493,815,989 in sales in 2024. The estimated EPS for RIGL in 2024 will be -$0.17 (minimum: -$0.26, maximum: -$0.10). (NASDAQ: RIGL) is expected to have a ROA of -11.96%, which is worse than the predicted 13.22% average for the US Biotechnology industry. (NASDAQ: RIGL) is expected to have a dismal ROE of N/A. In the last 12 months, RIGL has not distributed any dividends. RIGL Stock Forecast 2025 12 forecasts are made for each month of 2025 for the price of Rigel Pharmaceuticals stock, with an average price prediction of $1.68, a high prognosis of $1.81, and a low prediction of $1.38. The typical Rigel Pharmaceuticals stock estimate for 2025 shows a decline from the most recent price of $2.45000004768372 of -31.53%. RIGL Stock Forecast 2027 12 RIGL stock forecast are made for each monthly of 2027 for the RIGL stock forecast for 2027 (five years), with an average prediction of $1.17, a high prognosis of $1.27, and a low prediction of $1.11. The median RIGL stock forecast for 2027 demonstrates a decrease from the most latest market o

f $2.45000004768372 of -52.27%. RIGL Stock Forecast 2030 Twelve RIGL stock forecast are made to every month of 2030 regarding the RIGL stock forecast, with an average RIGL stock forecast of $1.02, a high prognosis of $1.08, and just a low RIGL stock forecast of $0.98. From the most latest price of $2.45000004768372 to the consensus Rigel Pharmaceuticals stock forecast 2030, a -58.49% decline has occurred. RIGL Stock Forecast 2032 Four RIGL stock forecast are made for each month of 2032 for the RIGL stock forecast for 2032 (10 years), with an average prediction of $0.93, a high prediction of $0.93, and a low prediction of $0.92. The typical RIGL stock forecast for 2032 shows a decline from the most recent price of $2.45000004768372 of -62.21%.

[cavixorg]

Here's what we can say about RIGL stock. A biotechnology business called Rigel Pharmaceuticals, Inc. finds and creates small molecule medications to treat cancer, uncommon immunological illnesses, and hematologic disorders. The business provides adults with chronic immune neutropenia Tavalisse, an oral splenic inhibitor of tyrosine kinase. Additionally, it produces the drug Fostamatinib, which is currently undergoing phase III clinical trials for the treatment of COVID-19, warm autoimmune hemolytic anemia, and COVID-19 patients who are hospitalized. The company is also working on R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor, which has successfully completed a phase I clinical trial for autoimmune and inflammatory diseases. As well as R289, a verbal interleukin understanding of the mechanism kinase 1/4 inhibitor, which is in phase I randomized study for autoimmune, inflammatory, and hematology-oncology diseases. Who Owns RIGL? Institutional investors own 73.88% of Rigel Pharmaceuticals (NASDAQ: RIGL), while insiders own 15.05% and individual investors own 11.07%. The largest individual shareholder of RIGL stock is Bvf Partners L P, which holds 16.66M shares, or 9.64% of the firm. Shares of Rigel Pharmaceuticals owned by Bvf Partners L P are presently valued at $13.89M. About RIGL It has research and license contracts with AstraZeneca AB for the development and marketing of R256, an inhaled JAK inhibitor, with BerGenBio AS for the development and marketing of AXL inhibitors in oncology, with Daiichi Sankyo for the development of murine double minute 2 inhibition for solid and cytological malignancies, and with Kissei Pharmaceutical Co., Ltd. for the licensing and supply of Fostamatinib. Additionally, the business and Eli Lilly and Company have a license agreement and a strategic partnership to co-develop and market R552 for a variety of indications, including inflammatory and autoimmune illnesses and other non-CNS disease development candidates. South San Francisco, California serves as the corporate headquarters for Rigel Pharmaceuticals, Inc. What Are The Consensus Ratings And Price Objective For Rigel Pharmaceuticals? The consensus recommendation for RIGL stock, based on the present 4 hold ratings and 3 buy ratings for RIGL stock, is Hold according to the ratings that 7 analysts have issued over the past year. With a high price goal of $15.00 and a low cost target of $1.00, Rigel Pharmaceuticals' average 12 month price forecast is $3.96. NASDAQ ticker RIGL stock is used to identify Rigel Pharmaceuticals when trading on the NASDAQ. Stock quotations for Rigel Pharmaceuticals may alternatively be shown as NASDAQ: RIGL. The current share price for Rigel Pharmaceuticals is $0.83 (NASDAQ: RIGL) (as of Dec 2, 2022). (NYSE MKT: RIGL) There are now 172,836,336 shares of Rigel Pharmaceuticals outstanding. The market capitalization of Rigel Pharmaceuticals is $144.15M, with the stock now selling at $0.83 per share. On November 29, 2000, RIGL stock went public at a price of $63.99. Your return over the past 22 years if you had purchased RIGL stock at $63.99 would have been -98.7%, for just an annualized return of -17.9%. Competitors Of RIGL Verastem (VSTM), Spectrum Pharmaceuticals (SPPI), Merrimack Pharmaceuticals (MACK), Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), Infinity Pharmaceuticals (INFI), Clovis Oncology (CLVS), Molecular Templates (MTEM), XOMA (XOMA), and Lexicon Pharmaceuticals are some of Rigel Pharmaceuticals' primary rivals (LXRX). Each of these businesses belongs to the "biotechnology" sector. Analysts favor other medical firms more than Rigel Pharmaceuticals. While the typical consensus recommendation for medical firms is Buy, Rigel Pharmaceuticals' rating is Hold. Verastem And Rigel Pharmaceuticals Verastem is outperformed by Rigel Pharmaceuticals in terms of earnings and revenue. Rigel Pharmaceuticals is currently the more cost-effective of the two stocks as it is selling at a cheaper cost ratio than Verastem.

With a beta of 0.63, Verastem's share price is predicted to be 37% less volatile than that of the S&P 500. When compared to the S&P 500, Rigel Pharmaceuticals does have a beta of 1.25, indicating that its RIGL stock price is 25% more volatile. When compared by MarketBeat users, Verastem received 150 more exceed votes than Rigel Pharmaceuticals. However, just 67.24% of individuals chose to vote for Verastem to outperform, compared to 69.61% who chose Rigel Pharmaceuticals. Institutional investors hold 58.6% of the shares of Verastem. Institutional investors now hold 80.9% of the shares of Rigel Pharmaceuticals. Insiders are the owners of 2.9% of the Verastem stock. Insiders own 6.4% of the shares of Rigel Pharmaceuticals, in contrast. A company's solid organizational ownership is a sign that hedge funds, big money managers, and endowments think it's prepared for long-term success. With a current consensus price objective of $5.00, Verastem might rise by 1,041.03%. With a $3.96 consensus price objective, Rigel Pharmaceuticals may rise by 374.91% from current levels. Analysts clearly perceive Verastem as being more favorable as Rigel Pharmaceuticals, given its higher consensus rating and more potential upside. What Date Will Rigel Pharmaceuticals Report Earnings? However, based on the report dates from the previous year, Rigel Pharmaceuticals estimates that its next earnings day will be on Tuesday, March 7, 2023. Rigel Pharmaceuticals (NASDAQ:RIGL) topped the analysts' consensus expectation of ($0.13) by $0.02 with its ($0.11) earnings per share (EPS) for the prior quarter. The reported yearly revenue for Rigel Pharmaceuticals (NASDAQ:RIGL) is $149.24 million. The reported net income for Rigel Pharmaceuticals (NASDAQ:RIGL) is -$17.91 million. Over the previous four quarters, RIGL's earnings per share were negative $0.48. Most Recent Analyst Recommendations From RIGL On December 2, 2022, Yigal Nochomovitz, a Citigroup bottom 6% analyst, increases RIGL to a solid investment rating. On November 4, 2022, Gary Nachman, a bottom 13% economist with BMO Capital, lowers their price objective for RIGL from $4 to $3 while maintaining a Buy recommendation. On August 18, 2022, Joseph Pantginis, rated bottom 10% analyst with HC Wainwright & Co., keeps RIGL with the a buy rating and increases their price objective from $7.00 to $15.00. On August 17, 2022, Do Kim, a high 33% analysts from Piper Sandler, retains RIGL with a hold recommendation and increases their price objective for the RIGL stock from $1.00 to $2.00. Financial Summary For RIGL Financial due diligence studies that RIGL passed show that it has a 70748000 cash burn. It has at least a year's worth of coverage in the form of cash and short-term investments. On the RIGL cash balance, short-term assets outnumber long-term liabilities. On the RIGL accounting records, short-term assets exceed short-term liabilities. Financial Due Diligence Tests that Fail: In the previous year, RIGL's profit margin decreased from -9.9% to -92.4%. The RIGL ratio of debt to equity is negative at -6.83. The total debt of RIGL is still negative. RIGL has $81.64M in short-term investments and cash. This is insufficient to fund its $70.75M yearly cash burn. Asset To Liability Ratio There are more short-term assets ($110.44M) than short-term liabilities ($47.27M) for RIGL. Long-term liabilities ($88.18M) are less than short-term assets ($110.44M) for RIGL. Since RIGL's debt to shareholder equity ratio (-6.83) is still negative, we do not take into account whether debt has decreased over the last five years. It is more concerning than a high ratio when RIGL's proportion of debt to equity (-6.83) is negative. Cash burn for the upcoming year ($70.75M) exceeds RIGL's cash & short-term investments ($81.64M). The profit margin for RIGL dropped by (-82.5%) in the previous year, going from (-9.9%) to (-92.4%). For at least a year, RIGL's cash & short-term investment ($81.64M) can fund its cash burn ($70.75M).

When factoring in a healthy margin of safety, RIGL ($0.83) is not considerably low (2.67%) in comparison to our estimate of its market valuation price of $0.86 based on the discounted cash flow (DCF) modeling. Scoring For RIGL Value: RIGL has a Value score of 14, which is higher than the industry average for Biotechnology. Right now, only one of RIGL's seven due diligence checks is passing. Finances: RIGL has a Financials score of 11, which is higher than the industry average for the Biotechnology sector. Only one of RIGL's seven due diligence checks is being passed. Forecast: The RIGL forecast score is 0, that is the same as the mean for the biotechnology sector. RIGL is failing 0 of 9 checks for due diligence. Performance: RIGL has a performance score of 43, which is higher than the average for the biotechnology sector. 3 from out 10 due diligence processes are being passed by RIGL. Dividend: Considering Rigel Pharmaceuticals hasn't recently paid dividends, we don't assign a score to this factor. How To Purchase Rigel Pharmaceuticals Stock Here are the six steps once more for purchasing Rigel Pharmaceuticals shares. Find out where to purchase shares in Rigel Pharmaceuticals. Open an account with a brokerage. Add your information after selecting your preferred payment method. Your brokerage account with the money. Analyze the shares of Rigel Pharmaceuticals. Purchase your RIGL product. Select whether you want to acquire RIGL stock at the spot price or at a preset price using a limit order. Get up-to-date information regarding your RIGL stock position. Make a watchlist of important changes regarding your new RIGL stock purchase.   RIGL Stock Forecast 2022 Six Wall Street analysts who follow NASDAQ: RIGL agree that the RIGL stock is a buy. Out of 6 analysts, 0 (%) suggest RIGL as a Sell, 0 (%) recommend RIGL as a Strong Sell, 1 (16.67%) recommends RIGL as a Strong Buy, 2 (33.33%) as a Buy, 3 (50%) as a Hold, and 0 (%) as a Hold Strong Sell. The revenue for Rigel Pharmaceuticals in 2022 is -$82,615,000. The average estimate of RIGL's 2022 profits from 5 Wall Street analysts is -$89,874,895, with the correct figure coming in at -$98,516,712 and the highest estimate coming in at -$81,233,078. RIGL Stock Forecast 2023 With the lowest RIGL earnings projection at -$82,961,441 and the highest RIGL statements forecast at -$36,295,631. 5 Wall Street analysts expect RIGL will earn -$57,035,991 in 2023. RIGL's revenue is expected to be $19,895,363,473 on average by 4 Wall Street analysts in 2023. The lowest RIGL revenue projection is $16,509,326,815, as well as the highest is $25,209,216,624. Analysts predict that RIGL's EPS will just be -$0.33 on average for 2023, with the lowest estimate being -$0.48 and the highest estimate being -$0.21. RIGL Stock Forecast 2024 With the lowest revenue RIGL stock forecast at $18,104,606,196 and the largest income RIGL stock forecast at $31,308,438,085, RIGL is expected to create $23,493,815,989 in sales in 2024. The estimated EPS for RIGL in 2024 will be -$0.17 (minimum: -$0.26, maximum: -$0.10). (NASDAQ: RIGL) is expected to have a ROA of -11.96%, which is worse than the predicted 13.22% average for the US Biotechnology industry. (NASDAQ: RIGL) is expected to have a dismal ROE of N/A. In the last 12 months, RIGL has not distributed any dividends. RIGL Stock Forecast 2025 12 forecasts are made for each month of 2025 for the price of Rigel Pharmaceuticals stock, with an average price prediction of $1.68, a high prognosis of $1.81, and a low prediction of $1.38. The typical Rigel Pharmaceuticals stock estimate for 2025 shows a decline from the most recent price of $2.45000004768372 of -31.53%. RIGL Stock Forecast 2027 12 RIGL stock forecast are made for each monthly of 2027 for the RIGL stock forecast for 2027 (five years), with an average prediction of $1.17, a high prognosis of $1.27, and a low prediction of $1.11. The median RIGL stock forecast for 2027 demonstrates a decrease from the most latest market o

f $2.45000004768372 of -52.27%. RIGL Stock Forecast 2030 Twelve RIGL stock forecast are made to every month of 2030 regarding the RIGL stock forecast, with an average RIGL stock forecast of $1.02, a high prognosis of $1.08, and just a low RIGL stock forecast of $0.98. From the most latest price of $2.45000004768372 to the consensus Rigel Pharmaceuticals stock forecast 2030, a -58.49% decline has occurred. RIGL Stock Forecast 2032 Four RIGL stock forecast are made for each month of 2032 for the RIGL stock forecast for 2032 (10 years), with an average prediction of $0.93, a high prediction of $0.93, and a low prediction of $0.92. The typical RIGL stock forecast for 2032 shows a decline from the most recent price of $2.45000004768372 of -62.21%.

[fbi-miles]

I have this too for a biography